CJC-1295 with DAC Purity Standards and Quality Control in Research Settings

Last Updated: May 18, 2026 | Author: Palmetto Peptides Research Team

When sourcing CJC-1295 with DAC for preclinical research, purity documentation is the single most important factor in determining whether experimental results will be reproducible and trustworthy. Research-grade CJC-1295 DAC should carry a minimum purity of 98% as confirmed by high-performance liquid chromatography (HPLC), along with mass spectrometry verification and a comprehensive Certificate of Analysis (COA). Without these quality standards, researchers cannot reliably attribute observed outcomes to the compound itself rather than to contaminants or synthesis byproducts.

DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.

This guide walks through the specific analytical methods used to assess CJC-1295 DAC purity, how to interpret a Certificate of Analysis, and what contamination thresholds matter most in a research context. Researchers working with growth hormone secretagogues must understand these standards before sourcing any lot.

What Is CJC-1295 with DAC and Why Purity Matters

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC modification — achieved through the addition of a maleimidoproprionic acid (MPA) linker that binds covalently to albumin — dramatically extends the peptide's half-life compared to unmodified CJC-1295. This half-life extension, from minutes to approximately six to eight days in rodent models, makes CJC-1295 DAC a useful tool in sustained growth hormone axis research [1].

Because of this extended bioactivity, any impurities present in a CJC-1295 DAC sample will also persist in vivo for an extended period. A low-purity lot introduces confounding biological activity that cannot be easily separated from the intended pharmacological signal. Truncated peptide sequences, oxidized residues, and synthesis byproducts all carry their own activity profiles that will contaminate study data if not controlled.

For these reasons, purity standards for CJC-1295 DAC are more stringent in practice than for shorter-half-life peptides. Most serious research institutions require 98% or higher purity by HPLC before accepting a lot for use.

Key Analytical Methods for Purity Verification

Reverse-Phase HPLC

Reverse-phase high-performance liquid chromatography (RP-HPLC) is the primary method for assessing peptide purity. In this technique, the compound is passed through a hydrophobic stationary phase, and components separate based on their affinity for the column. The resulting chromatogram shows peaks corresponding to each molecular species present in the sample.

For CJC-1295 DAC, researchers should expect to see a dominant single peak representing the target compound, with the area under that peak comprising at least 98% of total peak area. Secondary peaks at adjacent retention times typically represent truncated sequences, deletion sequences, or oxidized variants — all of which are synthesis artifacts with unpredictable biological activity.

A reputable supplier will provide a full HPLC chromatogram as part of the COA, not just a stated purity percentage. The chromatogram allows researchers to assess peak shape, the presence of shouldering, and the distribution of any minor impurities. A well-resolved, narrow primary peak with no shouldering is the ideal result.

Mass Spectrometry Confirmation

Mass spectrometry (MS) confirms the molecular identity of the compound. The expected molecular weight of CJC-1295 with DAC is approximately 3647.3 Da. Mass spec data should show a dominant molecular ion corresponding to this mass, typically presented as a series of multiply charged ions in electrospray ionization (ESI-MS) data.

ESI-MS is the preferred ionization method for peptides of this size. A well-characterized lot will show a clean spectrum with the expected charge state distribution and no major unexpected ions. Unexpected ions in the 1000-3000 Da range may indicate truncated sequences or adducts that warrant further investigation.

Some higher-end suppliers provide tandem mass spectrometry (MS/MS) data, which confirms the amino acid sequence by fragmenting the parent ion. This is the gold standard for sequence confirmation but is not universally required for research use if HPLC purity is strong.

Amino Acid Analysis

Amino acid analysis (AAA) provides a quantitative profile of the individual amino acids present after full hydrolysis of the peptide. This confirms that the correct residues are present in the expected ratios and can detect substitution errors that mass spectrometry might miss due to isobaric substitutions (amino acids of identical or very similar mass).

For CJC-1295 DAC, AAA is particularly useful for confirming the presence and ratio of unique residues like the modified lysine involved in the DAC linker. Some specifications will call out individual residue ratios against a theoretical standard.

Bacterial Endotoxin Testing

Even a 99% pure peptide sample can compromise research if it carries bacterial endotoxins (lipopolysaccharides, or LPS). Endotoxins are potent immune activators and will produce profound inflammatory responses in animal models at nanogram-per-kilogram concentrations. This is especially problematic in studies monitoring immune markers, inflammatory cytokines, or metabolic parameters.

The Limulus amebocyte lysate (LAL) test is the standard method for endotoxin detection. Research-grade peptides should meet a threshold of less than 1 EU/mg (endotoxin unit per milligram) for most in vitro applications, and less than 0.1 EU/mg for sensitive animal model work. A COA that omits endotoxin data should be treated with skepticism.

Sterility Testing

Sterility testing confirms the absence of viable microorganisms. For peptides reconstituted in bacteriostatic water for in vitro use, this is a secondary concern compared to endotoxins, but it remains part of a complete quality profile. Sterility testing is typically performed under USP <71> or equivalent protocols.

Understanding the Certificate of Analysis (COA)

The COA is the primary documentation artifact for a peptide lot. A complete COA for research-grade CJC-1295 DAC should include the following fields at minimum:

COA Field	What It Should Show	Minimum Standard
Compound Name / CAS	CJC-1295 with DAC; CAS 863288-34-0	Exact match required
Lot Number	Unique lot identifier traceable to synthesis batch	Must be present
HPLC Purity	Percentage of target peak area by RP-HPLC	≥98%
Molecular Weight	Confirmed by MS; ~3647.3 Da	±0.5 Da acceptable
Appearance	White to off-white lyophilized powder	No discoloration or clumping
Water Content	Karl Fischer titration result	≤8% typical for lyophilized peptides
Endotoxin Level	EU/mg by LAL test	<1 EU/mg
Sterility	Pass/fail per USP or equivalent	No growth
Test Date	Date testing was performed	Within 2 years typical

Researchers should cross-reference the lot number on the COA with the lot number printed on the vial label. Discrepancies between these identifiers are a red flag indicating either documentation error or, in the worst case, misrepresentation of the compound.

Common Purity Failures in CJC-1295 DAC

Oxidized Methionine Residues

CJC-1295 does not contain methionine, but related GHRH analogs often do, and synthesis conditions that work across multiple peptide products can introduce oxidative stress. More relevant to CJC-1295 DAC is oxidation of the tryptophan residue at position 8, which can produce +16 Da adducts visible on mass spec and as a secondary HPLC peak at a slightly earlier retention time than the parent compound. Tryptophan oxidation products typically retain partial biological activity but with altered receptor binding kinetics [2].

Truncated Sequences

Solid-phase peptide synthesis (SPPS) involves sequential addition of protected amino acid residues. Incomplete coupling at any step produces truncated sequences that lack some N-terminal or C-terminal residues. These fragments will appear as earlier-eluting peaks in RP-HPLC. Truncated sequences in CJC-1295 DAC are particularly concerning because N-terminal truncations destroy GHRH receptor binding activity while C-terminal truncations may preserve partial activity with an altered profile [3].

DAC Linker Hydrolysis

The maleimidoproprionic acid linker that gives CJC-1295 DAC its extended half-life can hydrolyze over time, particularly under non-ideal storage conditions. Hydrolysis removes the albumin-binding functionality, effectively converting the compound into standard CJC-1295 without DAC. This produces a compound with a much shorter half-life that will behave differently in in vivo studies. Mass spectrometry can detect this because the hydrolyzed form has a lower molecular weight.

This is why storage conditions matter. CJC-1295 DAC should be stored as lyophilized powder at -20°C or lower, protected from light and moisture. Once reconstituted, it should be stored at 4°C and used within the timeframe specified by the supplier. Reconstitution in bacteriostatic water rather than plain sterile water extends usable stability of the solution.

Acetate Salt Content

Peptides produced by SPPS are typically purified and lyophilized as trifluoroacetate (TFA) salts, which carry residual TFA that can interfere with some biological assays. Higher-quality suppliers perform ion exchange to convert the TFA salt to an acetate salt before lyophilization. The COA should specify the salt form, and researchers using sensitive cell-based assays should confirm the salt form is compatible with their system.

Comparing Purity Standards Across Research Applications

Application Type	Minimum HPLC Purity	Endotoxin Threshold	MS Confirmation Required?
Cell-free binding assays	95%	Not critical	Recommended
Cell culture (in vitro)	98%	<1 EU/mg	Yes
Rodent in vivo studies	98%	<0.5 EU/mg	Yes
Primate in vivo studies	99%	<0.1 EU/mg	Yes + AAA
Mechanistic pharmacokinetic studies	99%	<0.1 EU/mg	Yes + MS/MS

Third-Party vs. Supplier-Issued COA

A supplier-issued COA means the peptide manufacturer ran their own analytical tests on their own product. This is the standard in the industry but introduces a potential conflict of interest. For higher-stakes research applications, researchers often require a third-party COA, where an independent analytical laboratory performs the HPLC, MS, and endotoxin testing on a blinded sample.

Third-party testing adds cost and time but provides a higher level of confidence, particularly for novel lot purchases or when switching suppliers. Some research groups maintain relationships with contract research organizations (CROs) that can perform rapid turnaround peptide characterization on incoming lots.

When evaluating a supplier's COA, look for the name of the testing laboratory, instrument details (column type, gradient conditions, instrument model), and raw chromatogram data. A COA that shows only a final purity number without supporting chromatogram data is insufficient for serious research work.

Reconstitution and Handling to Preserve Purity

Even a certified high-purity lot can degrade rapidly with improper handling. Key practices to preserve CJC-1295 DAC integrity after receipt include:

• Keep the lyophilized vial at -20°C until ready to use
• Allow the vial to reach room temperature before opening to prevent condensation inside the vial
• Reconstitute with sterile bacteriostatic water using a slow, gentle injection along the vial wall rather than directly onto the powder cake
• Avoid vortexing; instead, gently swirl or roll the vial to dissolve the lyophilized cake
• Store reconstituted solution at 4°C and avoid repeated freeze-thaw cycles
• Use low-protein-binding tubes and pipette tips to minimize surface adsorption losses

Peptide adsorption to standard polypropylene is a well-documented issue for low-concentration solutions. At concentrations below 1 mg/mL, meaningful fractions of peptide can be lost to tube walls, effectively changing the actual concentration delivered in an experiment. Low-binding tubes mitigate this, as does working at higher stock concentrations and diluting immediately before use.

Red Flags When Evaluating a Supplier

Researchers evaluating potential sources for CJC-1295 DAC should be cautious when they encounter any of the following:

• COA with no lot number or a generic lot number shared across multiple products
• Purity stated as a range rather than a specific value
• No HPLC chromatogram provided or available on request
• No mass spec data or molecular weight confirmation
• Endotoxin testing absent from the COA
• No information about storage conditions during shipping
• Pricing significantly below market rate for research-grade peptides

Below-market pricing is particularly notable. The analytical testing required to produce a properly documented research-grade peptide lot adds meaningful cost per vial. Suppliers who cannot explain how they achieve very low pricing while providing full documentation are likely cutting corners somewhere in the process.

FAQs: CJC-1295 DAC Purity and Quality Control

What purity level is acceptable for CJC-1295 DAC in animal research?

Most institutional animal research protocols require a minimum of 98% purity by HPLC for peptide compounds administered to rodents. For primate studies or mechanistic pharmacokinetic work, 99% or higher is the appropriate standard. Anything below 95% should not be used in in vivo research.

Can I use CJC-1295 DAC with a COA from a previous lot for a new lot I just received?

No. COAs are lot-specific. Each synthesis batch has its own purity profile, impurity distribution, and endotoxin level. Using a COA from a different lot provides no meaningful quality assurance for the current lot.

What does it mean if the HPLC chromatogram shows a shoulder on the main peak?

A shoulder on the primary HPLC peak typically indicates co-eluting impurities that are not fully resolved from the main compound. Depending on the severity, this can indicate truncated sequences, partially oxidized variants, or DAC linker hydrolysis products. A well-purified lot should show a symmetrical, sharp primary peak with no shouldering.

How important is endotoxin testing for in vitro cell culture work?

Endotoxin contamination is highly relevant even for in vitro work. Many mammalian cell lines, particularly macrophage-lineage cells, respond strongly to endotoxins at very low concentrations. Even non-immune cells may show altered cytokine production or stress responses in the presence of endotoxin. Any research involving inflammatory markers or signaling pathways should use peptides with confirmed low endotoxin levels.

What is the difference between HPLC purity and biological potency?

HPLC purity measures the proportion of the target compound relative to all other species in the sample by area percentage. Biological potency measures functional activity at the target receptor. A sample could theoretically have 98% HPLC purity but reduced potency if the 2% impurities include receptor antagonists, or if the primary compound has undergone a subtle modification that reduces activity without significantly shifting retention time. This is why MS confirmation matters in addition to HPLC purity.

How should I dispose of CJC-1295 DAC research waste?

Peptide research waste should be disposed of according to your institution's chemical waste protocols. CJC-1295 DAC is a synthetic peptide and should be treated similarly to other biological research materials. Inactivation by dilute acid or alkaline conditions prior to disposal is standard practice for many research labs handling peptide compounds.

Does reconstitution solvent affect peptide purity?

Yes. Reconstitution with solutions that have extreme pH values or that contain incompatible excipients can accelerate degradation. Bacteriostatic water (0.9% benzyl alcohol in sterile water) is the standard reconstitution vehicle for research peptides like CJC-1295 DAC because benzyl alcohol provides mild antimicrobial protection while maintaining a pH compatible with peptide stability.

Citations

1. Jetté L, et al. "Growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lived GRF analog." Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
2. Stadtman ER. "Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions." Annual Review of Biochemistry. 1993;62:797-821. doi:10.1146/annurev.bi.62.070193.004053
3. Fields GB, Noble RL. "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids." International Journal of Peptide and Protein Research. 1990;35(3):161-214. doi:10.1111/j.1399-3011.1990.tb00939.x
4. Veber DF, et al. "The design of metabolically stable peptide analogs." Trends in Neurosciences. 1978;1(5):392-396.
5. Watt AP, et al. "Liquid chromatography-mass spectrometry in the quantitative analysis of peptides in biological fluids." Journal of Chromatography B. 2000;748(1):243-256. doi:10.1016/S0378-4347(00)00378-5
6. Bolstad N, et al. "Interference in immunoassays: avoiding known pitfalls." Scandinavian Journal of Clinical and Laboratory Investigation. 2013;73(7):545-553. doi:10.3109/00365513.2013.828278

DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.